News Gist .News

Articles | Politics | Finance | Stocks | Crypto | AI | Technology | Science | Gaming | PC Hardware | Laptops | Smartphones | Archive

Corbion Beats Expectations Despite Revenue Decline

Corbion, a Netherlands-based chemicals company, reported full-year 2024 earnings that beat analyst estimates, despite a decline in revenue of 11% compared to the previous year. The company's net income decreased by 37%, but its profit margin remained relatively stable at 3.6%. Looking ahead, Corbion forecasts growth of 5.1% per annum for the next three years.

See Also

Clariant Full Year 2024 Earnings: EPS Misses Expectations Δ1.85

Clariant's full-year 2024 earnings missed expectations, with revenue down 5.1% from FY 2023 and net income up 45%. The company's profit margin increased to 5.9%, driven by lower expenses, but the earnings per share (EPS) fell short of analyst estimates. Despite this, revenue is forecast to grow at a slower pace than the Chemicals industry in Switzerland over the next three years.

Seremban Engineering Berhad Second Quarter 2025 Earnings: EPS: RM0.004 (vs RM0.005 in 2Q 2024) Δ1.83

The conglomerate's second-quarter earnings report reveals a decline in revenue and net income, with significant drops of 40% and 18%, respectively. The company attributed the decrease to lower expenses, which contributed to an improvement in its profit margin from 0.8% to 1.1%. Despite this, Seremban Engineering Berhad's share price has remained relatively unchanged.

Bucher Industries Full Year 2024 Earnings: EPS Misses Expectations Δ1.82

Bucher Industries' full-year 2024 earnings fell short of expectations, with revenue declining 12% and net income dropping 36%. The company's profit margin also decreased to 7.2%, primarily due to lower revenue. Analysts had forecast a more resilient performance from the Swiss Machinery industry.

Cronos Group Full Year 2024 Earnings: Revenue Beats Expectations, Eps Lags Δ1.82

Cronos Group's full year 2024 earnings report shows revenue growth of 35% compared to the previous year, with a net income of US$41.1m, but missing analyst estimates by 2.0%. The company's profit margin has increased to 35%, and earnings per share (EPS) have declined to US$0.11, down from a loss of US$0.18 in the previous year. Revenue growth is forecasted to be 11% p.a. over the next three years.

Schroders Full Year 2024 Earnings: Beats Expectations Δ1.82

Schroders' full year 2024 earnings have exceeded analyst estimates by 1.0%, with revenue rising to UK£3.02 billion (up 1.0% from FY 2023). The company's net income also surged to UK£417.0 million (up 7.4% from FY 2023), driven by strong profit margins of 14%. These results demonstrate Schroders' ability to navigate challenging market conditions and deliver solid performance.

FIGS Full Year 2024 Earnings: Beats Expectations Δ1.82

FIGS reported a full-year revenue of $555.6 million for 2024, marking a 1.8% increase from the previous year, despite a significant drop in net income by 88%. The company's earnings per share surpassed analyst expectations, yet the profit margin fell to 0.5%, indicating rising expenses that have affected overall profitability. Looking ahead, FIGS anticipates an average revenue growth of 3.1% per year over the next three years, which lags behind the expected growth of the luxury industry in the U.S.

Holcim Full Year 2024 Earnings Miss Expectations Δ1.82

Holcim's full-year 2024 results missed analyst expectations, with revenue declining 2.2% to CHF26.4 billion and net income falling 3.8%. The company's profit margin remained steady at 11%, but earnings per share (EPS) missed estimates by 7.1%. Looking ahead, Holcim forecasts average annual revenue growth of 4.7% over the next three years.

Longeveron Full Year 2024 Earnings: Beats Expectations Δ1.81

Revenue exceeded analyst estimates by 11%, with net loss narrowing by 28% from FY 2023, and earnings per share surpassing expectations by 29%. The company's revenue growth is forecast to be 57% per annum for the next three years, outpacing the biotechs industry in the US at a 20% growth rate. These results position Longeveron as a promising player in the American biotechs industry.

e.on Full Year 2024 Earnings: Revenue Lags Amid Profit Growth Δ1.81

E.ON's full-year 2024 earnings revealed a profit margin of 4.8%, up from 0.5% in the previous year, driven by lower expenses and higher net income of €4.53b. The company's earnings per share (EPS) exceeded analyst estimates by 62%. However, revenue missed analyst expectations by 9.8%, coming in at €93.5b, down 1.6% from FY 2023.

Aimflex Berhad Full Year 2024 Earnings: EPS: RM0.006 (vs RM0.006 in FY 2023) Δ1.81

Aimflex Berhad's full year 2024 earnings report reveals a slight contraction in revenue and net income, with profit margins remaining relatively stable at 10%. The company's shares have taken a hit, falling 4% from the previous week, amidst concerns over its business performance. These results may be attributed to various factors, including market conditions, operational challenges, or strategic decisions.

South Bow Full Year 2024 Earnings: EPS Misses Expectations Δ1.81

South Bow reported a revenue increase to US$2.12 billion for the full year 2024, reflecting a 5.7% growth from the previous year. However, net income fell by 28% to US$316 million, resulting in a profit margin decrease from 22% to 15%, primarily due to rising expenses. The company's earnings per share (EPS) of US$1.52 missed analyst expectations by 15%, and future revenue growth is projected to remain flat, contrasting with the broader industry forecast.

Mosaic Full Year 2024 Earnings: Eps Misses Expectations Δ1.81

Mosaic's full-year 2024 earnings results show a significant decline, with revenue down 19% from the previous year and net income plummeting 85%. The company's profit margin has also decreased substantially, impacting its ability to generate earnings. Despite revenue growth forecasts for the next three years, the current performance is a cause for concern.

Ctac Reports Full Year 2024 Earnings Δ1.80

Ctac has reported its full-year 2024 financial results, revealing a revenue of €124.6 million, which reflects a 2.1% decline from the previous year. Despite the drop in revenue, net income surged by 245% to €3.91 million, resulting in an improved profit margin of 3.1% due to reduced expenses. Looking forward, the company anticipates a revenue growth of 4.4% annually over the next two years, slightly below the broader IT industry forecast in Europe.

Chart Industries Full Year 2024 Earnings: Misses Expectations Δ1.80

Chart Industries' full-year 2024 earnings exceeded analyst expectations, with revenue growing by 24% to US$4.16 billion and net income increasing by US$174.2 million to US$194.8 million. The company's profit margin expanded to 4.7%, driven by higher revenue, while earnings per share (EPS) rose to US$4.62, surpassing analyst estimates by 26%. Despite the positive results, revenue missed analyst expectations by 1.5%.

Supercomnet Technologies Berhad Full Year 2024 Earnings: EPS: RM0.037 (vs RM0.037 in FY 2023) Δ1.80

The Malaysian electrical industry's growth prospects remain intact, driven by Supercomnet Technologies Berhad's revenue expansion and forecasted 26% annual growth over the next three years. The company's net income has demonstrated a consistent upward trend, with a 7.8% increase from FY 2023. As the industry continues to evolve, investors should monitor the company's ability to maintain its profit margin at 21%.

South Plains Financial Full Year 2024 Earnings: Beats Expectations Δ1.80

South Plains Financial's full-year 2024 earnings exceeded analyst expectations, with revenue decreasing by 9.5% and net income down 21%. The company's profit margin declined to 26%, driven by lower revenue, while its EPS grew by 11% above estimates. Revenue is forecast to grow 6.9% on average over the next two years.

Capricorn Energy's Exceptional Past Performance Despite Current Struggles Δ1.80

The total shareholder return of 138% over the last three years highlights the significant returns generated by Capricorn Energy's investors, despite the company's struggles to make a profit in the same period. The revenue growth of 38% per year compound is particularly noteworthy, considering most pre-profit companies struggle to achieve such rates. However, the share price has moved in the opposite direction, down 19% over three years, suggesting market concerns about the company's sustainability.

Weir Group's Full Year 2024 Earnings Beat Expectations, Revenue Lags Δ1.80

Hedge your bets on Weir Group's full-year earnings report, which saw a 38% increase in net income despite revenue dropping by 4.9%. The company's profit margin expanded to 13%, driven by lower expenses. The growth rate of Weir Group's shares has outpaced the forecasted growth rate for the Machinery industry in the United Kingdom.

Par Technology Full Year 2024 Earnings: Eps Beats Expectations, Revenues Lag Δ1.80

PAR Technology's full year 2024 earnings beat analyst expectations, but revenue missed estimates by 16%, with a net loss widening by 29% from the previous year. The company's shares have increased by 10% over the past week, driven by its strong EPS performance. However, the revenue decline and widening losses raise concerns about the company's financial health.

Encorp Berhad Posts Modest Profit as Revenue Declines Δ1.80

Encorp Berhad's full-year 2024 earnings report revealed a modest profit of RM1.81m, up from a significant loss of RM9.19m in FY 2023, driven by lower expenses. The company's revenue declined by 20% to RM104.0m, a decrease attributed to various market and economic factors. Despite the challenges, Encorp Berhad's net income margin expanded to 1.7%, showcasing the company's efforts to optimize its operations.

Cardiff Oncology Beats Expectations in Full Year 2024 Earnings Δ1.80

Cardiff Oncology's full year 2024 earnings have exceeded analyst estimates, with a net loss of US$45.5m and a loss per share of US$0.95, wider than the previous year's loss of US$0.93. The company's revenue surpassed expectations by 12%, beating forecasts for growth in the biotechs industry in the US. Looking ahead, Cardiff Oncology's revenue is forecast to grow at an average rate of 52% per annum over the next three years.

Kia Lim Berhad Full Year 2024 Earnings: Revenue Surge with EPS Increase Δ1.80

Kia Lim Berhad's full-year 2024 earnings report reveals a revenue surge of 22% from the previous year, driven by strong financial performance. The company's net income has also seen an upward trend, increasing by 17% compared to the same period last year. However, the profit margin remains unchanged at 13%. Kia Lim Berhad shares have experienced a decline of 7.8% from a week ago.

K. Seng Seng Corporation Berhad Earnings Reveal Resilience Amid Downward Trend Δ1.80

K. Seng Seng Corporation Berhad's Full Year 2024 earnings report shows a profit margin of 2.6%, up from a net loss in FY 2023, as revenue increased by 21% to RM297.7m. The company's EPS has also shown improvement, with a positive value of RM0.048 compared to the RM0.098 loss in FY 2023. Despite its down 3.4% performance from a week ago, K. Seng Seng Corporation Berhad's earnings suggest the company is better positioned than previously thought.

Engtex Group Berhad Sees Slight Earnings Growth in FY2024 Amid Market Uncertainty Δ1.80

The Engtex Group Berhad reported a slight increase in earnings per share (EPS) for the full year 2024, rising to RM0.014 from RM0.013 in FY2023, driven by a net income of RM10.8m, up 6.2% from last year. The company's revenue remained flat at RM1.46b, while its profit margin stayed consistent at 0.7%. Despite this growth, the company's shares have fallen 11% in the past week, indicating market concerns.

Methanex Full Year 2024 Earnings: Misses Expectations Δ1.80

Methanex reported its full year 2024 financial results, revealing flat revenue of $3.72 billion and a 5.8% decline in net income to $164 million, falling short of analyst expectations. The company's earnings per share also missed forecasts by 17%, reflecting a profit margin decrease from 4.7% to 4.4%. Despite these setbacks, Methanex anticipates a 10% annual revenue growth over the next three years, outpacing the broader Canadian chemicals industry.